APA (7th ed.) Citation

Coccia, P. A., Alconcher, L. F., Ferraris, V., Lucarelli, L. I., Grillo, M. A., Arias, M. A., . . . Sánchez-Luceros, A. (2025). Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome. Pediatric nephrology (Berlin, West), 40(4), 1041-1047. https://doi.org/10.1007/s00467-024-06530-2

Chicago Style (17th ed.) Citation

Coccia, Paula A., et al. "Eculizumab as First-line Treatment for Patients with Severe Presentation of Complement Factor H Antibody–mediated Hemolytic Uremic Syndrome." Pediatric Nephrology (Berlin, West) 40, no. 4 (2025): 1041-1047. https://doi.org/10.1007/s00467-024-06530-2.

MLA (9th ed.) Citation

Coccia, Paula A., et al. "Eculizumab as First-line Treatment for Patients with Severe Presentation of Complement Factor H Antibody–mediated Hemolytic Uremic Syndrome." Pediatric Nephrology (Berlin, West), vol. 40, no. 4, 2025, pp. 1041-1047, https://doi.org/10.1007/s00467-024-06530-2.